Company News & Events

Preclinical Efficacy Data on Sickle Cell Disease of ORY-3001, a LSD1 inhibitor from ORYZON, to be presented at ASH 2017

4 December 2017


• Research in mice and baboons has been done by the University of Illinois at Chicago

• Oral Presentation on December 10th to be delivered by Prof. D. Lavelle

• Oryzon’s CEO will attend the Conference

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced that preclinical efficacy data of its investigational drug ORY-3001, a selective LSD1 inhibitor, will be presented at an oral presentation at the American Society of Hematology (ASH) 59th Annual Meeting and Exposition, being held December 9-12, 2017 in Atlanta, GA.
Professor Donald Lavelle from the Department of Medicine, University of Illinois at Chicago, Jesse Brown VA Medical Center, Chicago, IL, who has led the collaborative research, will present the communication entitled “Oral Administration of the LSD1 Inhibitor OG-S1335 Increases Fetal Hemoglobin in Humanized Transgenic Sickle Cell Disease Mice and in Baboons”.


Click here to see the full Press Release


Posted In: 

Share this story